Search Within

Martin Henner Voss

Formats
  1. Meeting Abstract (154)
  2. Journal Article (124)
  3. Review (6)
  4. Editorial (5)
  5. Guidelines (2)
  6. Research Letter (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (294)
  2. Genitourinary Oncology Service (294)
  3. Solid Tumor Oncology Division (294)
  4. Weinberg Fellows (108)
  5. Human Oncology and Pathogenesis Program (106)
  6. Surgery (106)

More Groups

People
  1. Robert Motzer (178)
  2. Abraham Hakimi (97)
  3. Darren Feldman (81)
  4. Chung-Han Lee (75)
  5. Maria Carlo (68)
  6. Ritesh Kotecha (65)

More People

Years
  1. 2025 (12)
  2. 2024 (15)
  3. 2023 (21)
  4. 2022 (24)
  5. 2021 (30)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (120)
  2. Clinical Cancer Research (18)
  3. BJU International (15)
  4. Annals of Oncology (13)
  5. Journal for ImmunoTherapy of Cancer (12)
  6. Clinical Genitourinary Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (124)
  2. American Association for Cancer Research (26)
  3. Wiley Blackwell (22)
  4. Elsevier Inc. (21)
  5. Oxford University Press (19)
  6. Biomed Central Ltd (15)

More Publishers

Results (294)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Deciphering radiological stable disease to immune checkpoint inhibitors
    Journal Article

    Luo, J.; Wu, S.; Rizvi, H.; Zhang, Q.; Egger, J. V.; Osorio, J. C.; Schoenfeld, A. J.; Plodkowski, A. J.; Ginsberg, M. S.; Callahan, M. K.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine
    Journal Article

    Herati, R. S.; Knorr, D. A.; Vella, L. A.; Silva, L. V.; Chilukuri, L.; Apostolidis, S. A.; Huang, A. C.; Muselman, A.; Manne, S.; Kuthuru, O.; more...
    Nature Immunology (2022)

    Fulltext@MSK | Save
  • Up-front nivolumab with or without salvage ipilimumab across International Metastatic Database Consortium risk groups in metastatic clear cell renal cell carcinoma
    Editorial

    Voss, M. H.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A randomized phase II study of MEDI0680 in combination with durvalumab versus nivolumab monotherapy in patients with advanced or metastatic clear-cell renal cell carcinoma
    Journal Article

    Voss, M. H.; Azad, A. A.; Hansen, A. R.; Gray, J. E.; Welsh, S. J.; Song, X.; Kuziora, M.; Meinecke, L.; Blando, J.; Achour, I.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Phase II study of neoadjuvant nivolumab in patients with locally advanced clear cell renal cell carcinoma undergoing nephrectomy
    Journal Article

    Carlo, M. I.; Attalla, K.; Mazaheri, Y.; Gupta, S.; Yildirim, O.; Murray, S. J.; Coskey, D. T.; Kotecha, R.; Lee, C. H.; Feldman, D. R.; more...
    European Urology (2022)

    Fulltext@MSK | Save
  • PIVOT IO 011: A phase 1/2 study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) and tyrosine kinase inhibitor (TKI) versus NIVO and TKI alone in patients (pts) with previously untreated advanced or metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Voss, M. H.; Tykodi, S. S.; Grimm, M. O.; Hammers, H. J.; Rini, B. I.; Tannir, N. M.; Qureshi, A. H.; Tsipouri, V.; Hodari, M.; Ravimohan, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma
    Meeting Abstract

    Kotecha, R.; Lee, C. H.; McHugh, D. J.; Dadoun, C.; Knezevic, A.; Carlo, M. I.; Feld, E.; Shapnik, N.; Shah, N. J.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients
    Meeting Abstract

    Lacouture, M. E.; Patel, A. B.; Le Boeuf, N. R.; Marathe, O. S.; Leventhal, J.; Choi, J. N.; Lam, E. T.; Kaffenberger, B. S.; Voss, M. H.; Webb, M. L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Choueiri, T. K.; Plimack, E. R.; Powles, T.; Voss, M. H.; Gurney, H.; Silverman, R. K.; Perini, R. F.; Rodriguez-Lopez, K.; Rini, B. I.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: An open-label phase I trial
    Journal Article

    Meric-Bernsta, F.; Tannir, N. M.; Iliopoulos, O.; Lee, R. J.; Telli, M. L.; Fan, A. C.; DeMichele, A.; Haas, N. B.; Patel, M. R.; Harding, J. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save